LOGO
LOGO

ALX Oncology Pursues Multiple Near-Term Catalysts For Two Novel Cancer Treatments

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
scientistinvestors 20022026 lt

ALX Oncology Holdings Inc. (ALXO), a clinical-stage biotechnology company, has data readouts scheduled this year for two of its clinical programs, which could determine the future of its therapeutic candidates.

The company is focused on developing highly differentiated medicines that optimise the immune system's ability to fight cancer and fully deliver on the promise of innovative cancer therapies. Its pipeline includes two clinical drug candidates - Evorpacept and ALX2004.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update: April 13 – April 17, 2026

April 17, 2026 15:29 ET
The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.